Amneal Pharmaceuticals Reports Q3 2026 Revenue of $863 Million, Adjusted EPS of $0. ...
Revenue grows 10% as Affordable Medicines and Specialty segments post double-digit gains; full-year guidance raised again Related Stocks: AMRX ,
Revenue grows 10% as Affordable Medicines and Specialty segments post double-digit gains; full-year guidance raised again Related Stocks: AMRX ,